Listening to the CC yesterday, I had come to the exact same conclusion.
The purpose of the CC call seemed to have been singularly, to impress and awe the non medical investor population with smoke and mirrors revolving around the results of their research.
Once again, we have a company focused on the price of their stock and promotion of stock, rather than the business of the company, a major red flag. Selling stock below current prices being a second red flag. and there are more flags if one looks further.
additionally:
Geron (GERN: news, chart, profile) gave back nearly 9 percent to $5 after the Menlo Park, Calif., biotechnology firm said it's agreed to sell 4 million shares of its common stock to two investors for $4.60 per share. The sale will yield gross proceeds of $18.4 million.
Granted, early in the presentation, there was a brief mention of the perfunctory safe harbors clause and regarding possible risks of investments in general. ..., but clearly, the cc attempted in giving an impression of "breaking edge research" and "on the cutting edge" of a possible cure for cancer, which GERN is nowhere near.
It is satisfying to read this article. At least someone is looking out for the welfare of the naive investing public, albeit perhaps too late for some.
fwiw, imho, this is a $2 stock. |
